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Abstract
O -GlcNAc glycosylation is a unique, dynamic form of glycosylation found on intracellular
proteins of all multicellular organisms. Studies suggest that O-GlcNAc represents a key regulatory
modification in the brain, contributing to transcriptional regulation, neuronal communication and
neurodegenerative disease. Recently, several new chemical tools have been developed to detect
and study the modification, including chemoenzymatic tagging methods, quantitative proteomics
strategies and small-molecule inhibitors of O-GlcNAc enzymes. Here we highlight some of the
emerging roles for O-GlcNAc in the nervous system and describe how chemical tools have
significantly advanced our understanding of the scope, functional significance and cellular
dynamics of this modification.
O-GlcNAc glycosylation, the covalent attachment of β-N-acetylglucosamine to serine or
threonine residues of proteins, is an unusual form of protein glycosylation1 (Fig. 1). Unlike
other types of glycosylation, this single-sugar modification occurs on intracellular proteins
and is not elaborated further into complex glycans. The O-GlcNAc transferase (OGT)
enzyme is a soluble protein that is found in the cytosol, nucleus and mitochondria2, rather
than in the endoplasmic reticulum or Golgi. The dynamics of O-GlcNAc are also unique
among sugar modifications, being cycled on a shorter time scale than protein turnover3.
Thus, in many respects O-GlcNAc is more akin to phosphorylation than to conventional
forms of glycosylation.
Several reviews have described the roles of O-GlcNAc in cellular processes, such as
transcription2,4, the stress response5,6, apoptosis7,8, signal transduction2,9, glucose
sensing5,10 and proteasomal degradation5. Only a few reviews have highlighted the
importance of O-GlcNAc glycosylation in the nervous system, and those reports have
focused on its potential impact on neurodegenerative diseases11,12. However, several lines
of evidence suggest that O-GlcNAc has crucial roles in both neuronal function and
dysfunction. The enzymes responsible for the modification are most highly expressed in the
brain13,14 and are enriched at neuronal synapses15,16. Neuron-specific deletion of the OGT
gene in mice leads to abnormal development and locomotor defects, resulting in neonatal
death17. The O-GlcNAc modification is abundant in the brain and present on many proteins
important for transcription, neuronal signaling and synaptic plasticity, such as cAMP-
responsive element binding protein (CREB)18, synaptic Ras GTPase-activating protein
(synGAP)19 and β-amyloid precursor protein (APP)20. An intriguing interplay between O-
GlcNAc glycosylation and phosphorylation has been observed in cerebellar neurons,
wherein activation of certain kinase pathways reduces O-GlcNAc levels on cytoskeleton-
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associated proteins21. Finally, recent studies suggest that O-GlcNAc is dynamically
regulated by excitatory stimulation of the brain in vivo19.
Over the past 5 years, new chemical approaches have been developed to meet the specific
challenges associated with studying O-GlcNAc glycosylation in the brain. Methods for
chemically tagging and identifying O-GlcNAc–glycosylated proteins have vastly expanded
the number of neuronal proteins known to be O-GlcNAc modified. New pharmacological
inhibitors of the O-GlcNAc enzymes have been discovered that may overcome some of the
limitations of genetic approaches. Quantitative proteomics strategies designed to
accommodate postmitotic neurons and brain tissue have been used to monitor changes in
glycosylation levels in response to neuronal stimuli. Combined with recent advances in mass
spectrometry, these powerful tools have provided an unprecedented opportunity to explore
the O-GlcNAc proteome, manipulate glycosylation levels and study the dynamics of this
modification in vivo.
In this Review, we describe emerging functions for O-GlcNAc glycosylation in the nervous
system. We then consider the modification in the context of chemical biology, describing
chemical approaches that have accelerated an understanding of O-GlcNAc and chemical
tools needed to further advance the field.
The enzymes OGT and OGA
OGT and β-N-acetylglucosaminidase (OGA or O-GlcNAcase) catalyze the reversible
addition and removal of O-GlcNAc, respectively. Both enzymes are most highly expressed
in the brain and exist as several different isoforms2,22. Three distinct isoforms of OGT have
been identified, including a 110-kDa and a 78-kDa isoform, which can assemble into
multimers23,24, and a smaller mitochondrial isoform. Each variant contains a C-terminal
catalytic domain, but differs in the number of tetratricopeptide repeats (TPRs) within its N-
terminal domain. The TPRs serve as protein-protein interaction modules that appear to target
OGT to accessory proteins and potential substrates, such as the GABAA receptor interacting
factor-1 (GRIF-1)25 and the related O-GlcNAc transferase interacting protein (OIP106)25,
which have been implicated in mitochondrial trafficking to synapses26,27, and the
transcriptional repressor complex mSin3A–histone deacetylase 1 (HDAC1)28. In addition,
OGT forms a complex with protein phosphatase-1 (PP1) in the brain29. The association
between OGT and PP1 is particularly intriguing, as it may provide a direct mechanism to
couple O-GlcNAc glycosylation to dephosphorylation of specific substrates. Although OGT
is found in the nucleus, cytosol and mitochondria, it is particularly enriched in the nucleus15
and the soluble synaptic compartment16.
Like OGT, OGA seems to be highly active at neuronal synapses16, and it is also found in the
nucleus and cytosol30. OGA contains an N-terminal glycosidase domain and a putative C-
terminal histone acetyltransferase (HAT) domain31. Two distinct isoforms of OGA exist, a
130-kDa and a 75-kDa variant, which share the same catalytic domain but differ in their C
terminus32. The potential HAT activity of OGA may provide an interesting mechanism for
coupling deglycosylation of nuclear proteins to transcriptional activation. As with OGT,
OGA has been shown to interact with specific proteins, including calcineurin (also known as
protein phosphatase-2B), amphiphysin and dihydropyrimidinase-related protein 2 (DRP2,
also known as CRMP1)30.
Transcriptional regulation
Early studies revealed that the O-GlcNAc modification is enriched on chromatin33 and is
found on RNA polymerase II and many of its transcription factors34. As described in several
reviews2,4,35, O-GlcNAc glycosylation has been shown to both enhance and suppress the
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activity of transcription factors. O-GlcNAc can disrupt protein-protein interactions, as in the
case of Sp1, whose glycosylation represses transcription at Sp1-driven promoters36,37. In
other cases, it can promote protein-protein interactions, as in the case of signal transducer
and activator of transcription 5A (STAT5A), whose glycosylation enhances its activity by
recruiting the transcriptional coactivator CREB-binding protein (CBP)38. O-GlcNAc may
also play a more general role in transcriptional repression through a mechanism involving
the targeting of OGT to an HDAC1 complex by the corepressor mSin3A28. In addition to
altering protein-protein interactions, O-GlcNAc can affect post-translational modifications.
For instance, glycosylation stabilized the tumorsuppressor protein p53 by decreasing its
phosphorylation and subsequent degradation by the proteasome39.
Much less is known about the transcriptional roles of O-GlcNAc in the brain. However,
CREB, a transcription factor important for neuronal survival, long-term memory storage and
drug addiction40,41, was shown to be O-GlcNAc glycosylated in the rodent brain18.
Glycosylation occurred at two major sites within the Q2 transactivation domain of CREB
and disrupted binding of CREB to TAFII130, a component of the basal transcriptional
machinery. As a result, glycosylation repressed the transcription of CRE-mediated genes
both in vitro and in cells18. It will be interesting to investigate whether glycosylation of
CREB is dynamically regulated in neurons, and whether it downregulates specific genes
associated with memory storage and cell survival.
Early growth response-1 (EGR1), a transcription factor important for neuronal survival and
long-term memory storage42,43, was also recently shown to be O-GlcNAc modified in the
brain19. Notably, glycosylation of EGR1 was found to be dynamically modulated by
excitatory stimulation of the brain in vivo. Stimulation of rats with the glutamate receptor
agonist kainic acid led to a ten-fold increase in glycosylation of EGR1 within its
transactivation domain19. Although the functional implications of this response will require
further investigation, these studies raise the exciting possibility that neuronal activity
regulates the transcriptional activity of EGR1 by modulating EGR1 glycosylation levels.
Proteomic studies of O-GlcNAc–modified proteins from the brain have also underscored the
importance of O-GlcNAc in regulating transcription. Approximately one-quarter of the
neuronal O-GlcNAc–modified proteins known to date are transcriptional regulatory
proteins19,44 (Fig. 2). This includes numerous transcription factors (for example, SRY box–
containing gene 2 (SOX2), activating transcription factor 2 (ATF2) and EGR1), as well as
transcriptional coactivators (steroid receptor coactivator-1 (SRC1)), repressors (p66β and
BRAF-HDAC complex 80 (BHC80)) and corepressors (transducin-like enhancer of split 4
(TLE4), carbon catabolite repression 4-negative on TATA-less (CCR4–NOT)). For instance,
SOX2 is a member of the high-mobility group box (HMG) superfamily of minor groove
DNA binding proteins, and it functions to regulate transcription on different promoters
depending on its interactions with specific protein partners45. SOX2 interacts with proteins
through its highly conserved HMG DNA binding domain, which also contains its O-GlcNAc
modification site44. One of the well-established functions of SOX2 is its crucial role in the
maintenance of embryonic stem cell pluripotency in partnership with OCT4 (also known as
POU5F1)46. In the adult rat brain, SOX2 expression has been reported to occur in actively
dividing adult neuronal precursor cells and in neurogenic astroglia47. Another example of
the expanding role of O-GlcNAc in transcription is the modification of two proteins
(including a ubiquitin ligase) in CCR4–NOT44, a large protein complex involved in mRNA
metabolism and in the global control of gene expression48. Together with earlier studies
demonstrating glycosylation of RNA polymerase II, these findings suggest that O-GlcNAc
participates in regulating several aspects of transcription.
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Synaptic proteins and neuronal communication
Consistent with the observation that OGT and OGA are highly active at synapses, proteomic
studies have uncovered a number of synaptic proteins in the O-GlcNAc proteome19,44,49,50
(Fig. 2). Many of these proteins are enriched in the postsynaptic density, where they
participate in the regulation of dendritic spine morphology and associate with the
cytoskeleton. For instance, synaptopodin44, synGAP19, and SH3 and multiple ankyrin repeat
domains protein 2 (SHANK2)49 are crucial for the normal formation of dendritic spine
apparatuses51–53, and synaptopodin and δ-catenin have important roles in learning and
memory51,54.
O-GlcNAc modifications are also highly abundant in presynaptic terminals. Several proteins
involved in neurotransmitter release or synaptic vesicle endocytosis, such as bassoon44,
piccolo49, synapsin49 and clathrin assembly protein (AP180)55, are O-GlcNAc glycosylated.
The O-GlcNAc–modified collapsin response mediator protein 2 (CRMP2, also known as
DPYSL2)19 has key roles in axon formation, elongation and branching56. Moreover, many
cytoskeletal proteins themselves are known to be glycosylated, including tau57, the
neurofilament proteins NF-H58, NF-L49 and NF-M49, and the microtubule-associated
proteins MAP1B44 and MAP2B44.
Additional functional studies are needed to define the mechanisms by which O-GlcNAc
regulates these proteins. Nonetheless, its prevalence on proteins intricately involved in
neurotransmitter release and cytoskeletal rearrangements underlying synaptic plasticity
suggests roles for O-GlcNAc in regulating key neuronal functions. As described below,
emerging evidence indicates that O-GlcNAc levels can be dynamically modulated in
response to neuronal stimuli. Moreover, the potential interplay between O-GlcNAc and
kinase pathways in neurons may provide a powerful means to control protein function and
modulate neuronal communication processes.
Neurodegenerative disease
O-GlcNAc glycosylation has been implicated in several neurodegenerative diseases, such as
Alzheimer’s disease57,59,60 and amyotrophic lateral sclerosis (ALS)61. The genes encoding
OGA and OGT map to chromosomal regions associated with late-onset Alzheimer’s
disease62 and dystonia-Parkinsonism syndrome63, respectively. Moreover, O-GlcNAc levels
are abnormally altered in the brains of individuals with Alzheimer’s disease, although the
magnitude and direction of the change seems to depend on the subcellular protein
fraction59,60.
In the pathology of Alzheimer’s disease, the microtubule protein tau becomes
hyperphosphorylated, which in turn favors its aggregation to form neurofibrillary tangles,
which are hallmarks of the disease64. Tau is extensively O-GlcNAc glycosylated in the adult
rat brain, although the estimated 12 or more modification sites have yet to be mapped57.
Importantly, several studies suggest that O-GlcNAc glycosylation of tau negatively regulates
its ability to be phosphorylated. For instance, inducing tau glycosylation with OGA
inhibitors or by overexpression of OGT decreases tau phosphorylation at specific sites60,65.
Conversely, stimulation of hyperphosphorylated tau using the phosphatase inhibitor okadaic
acid leads to hypoglycosylated tau in human neuroblastoma cells66. Neuron-specific
deletion of the OGT gene in mice induces hyperphosphorylated tau similar to that found in
Alzheimer’s disease17. As impaired glucose uptake and metabolism have been linked to
Alzheimer’s disease and seem to worsen as the disease progresses67, one theory is that tau
glycosylation becomes reduced in affected individuals, leading to hyperphosphorylated tau.
Consistent with this view, mouse models of starvation that mimic this impaired glucose
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metabolism show reduced tau glycosylation and a corresponding increase in tau
phosphorylation at specific sites60,68.
Abnormal O-GlcNAc glycosylation may also contribute to neurodegenerative diseases in
more diverse ways. The amyloid precursor protein (APP), which forms the β-amyloid
plaques characteristic of Alzheimer’s disease, is both O-GlcNAc glycosylated and
phosphorylated20. In an animal model of ALS, the O-GlcNAc levels of neurofilament
protein M are decreased at the same time as its phosphorylation levels are increased61.
Finally, O-GlcNAc glycosylation has been demonstrated to inhibit the proteasome69, thus
providing a mechanism to couple ubiquitin-mediated protein degradation to the general
metabolic state of the cell. Blocking the removal of O-GlcNAc from the proteasome leads to
increased protein ubiquitination69 and possibly neuronal apoptosis70. Proteasomal
dysfunction and ubiquitinated inclusion bodies are found in the diseased tissue of
individuals with ALS, Parkinson’s disease, Huntington’s disease and Alzheimer’s disease71.
Thus, aberrations in glucose metabolism and the O-GlcNAc glycosylation of specific
proteins have been associated with several neurodegenerative disorders. It will be important
to determine the extent to which such changes are crucial to the development and
progression of these diseases.
O-GlcNAc dynamics and cycling
A unique feature of O-GlcNAc glycosylation is its ability to undergo dynamic cycling, in
contrast to other, more static forms of protein glycosylation. Studies have shown that O-
GlcNAc levels are altered by extracellular stimuli on a similar time scale to phosphorylation.
For instance, a transient increase in glycosylation of the transcription factor nuclear factor
activated T cells (NFAT) was observed within 5 min after T- or B-cell activation72.
O-GlcNAc levels are highly responsive to glucose concentrations and influx through the
hexosamine biosynthesis pathway (HBP) in neurons and other cell types73,74.
Approximately 2–5% of all cellular glucose is metabolized through the HBP pathway to
generate UDP-GlcNAc75. As OGT activity is exquisitely sensitive to UDP-GlcNAc
concentrations76, O-GlcNAc glycosylation may act as a sensor for the general metabolic
state of the cell. Consistent with this idea, O-GlcNAc has been intricately linked to cell
survival17 and is induced by many forms of cell stress77.
In the brain, phosphorylation serves as a central mechanism for neuronal communication by
regulating ion channels, neurotransmitter receptors, gene transcription and synaptic vesicle
release78,79. Protein kinases and phosphatases work together to coordinate different forms of
synaptic plasticity, and they are necessary for the induction and maintenance of postsynaptic
long-term potentiation and longterm depression80. Thus, the potential interplay between O-
GlcNAc glycosylation and phosphorylation has exciting implications for many neuronal
functions. Early studies showed that activation of protein kinase C (PKC) or cAMP-
dependent protein kinase (PKA) significantly decreased overall O-GlcNAc glycosylation in
the cytoskeletal protein fraction of cultured cerebellar neurons21. Conversely, inhibition of
PKC, PKA, cyclin-dependent protein kinases or S6 kinase increased overall O-GlcNAc
levels in these fractions. A more complex relationship was observed with tyrosine kinases
and phosphatases: inhibition of tyrosine phosphatases led to a decrease in overall O-GlcNAc
levels, whereas inhibition of tyrosine kinases induced both increases and decreases in O-
GlcNAc, depending on the protein fraction.
O-GlcNAc also seems to have important signaling functions that are independent of its
relationship to phosphorylation. Recent quantitative proteomics studies have shown that O-
GlcNAc glycosylation is dynamic and is induced by excitatory neuronal stimuli in vivo19.
Dynamic changes in O-GlcNAc glycosylation of specific proteins were observed when rats
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were administered kainic acid, which activates multiple excitatory signaling pathways
involved in the stress response and synaptic plasticity. The increases in glycosylation
reached a maximum after 6 hours and then returned to basal levels, demonstrating the
reversible nature of O-GlcNAc in the brain. Interestingly, not all of the O-GlcNAc–modified
proteins showed site-specific increases in glycosylation, suggesting that O-GlcNAc is
subject to complex regulation within neurons.
Altogether, the emerging evidence suggests that O-GlcNAc represents a key regulatory
modification in the brain. Not only is it present on many functionally important proteins, it
seems to be reversible, differentially regulated and responsive to neuronal activity. Further
studies are needed to elucidate the molecular mechanisms involved and how activation of
specific signaling pathways leads to the regulation of OGT and OGA. Moreover, with the
exception of the last example, changes in O-GlcNAc glycosylation have been monitored
only on a global level, and the specific proteins undergoing dynamic changes in
glycosylation remain largely unknown. As described below, new chemical approaches are
being developed that should enable such questions to be addressed and provide new insights
into the complex cellular dynamics of O-GlcNAc.
Chemical approaches to address the challenges of O-GlcNAc
Recent advances in our understanding of the cellular functions of O-GlcNAc have been
accelerated by the development of chemical tools for studying the modification. Although
O-GlcNAc glycosylation was discovered more than 20 years ago, its extent and functional
significance are only beginning to be understood. A major challenge has been the difficulty
of detecting and studying the modification in vivo. Like other post-translational
modifications, O-GlcNAc is often dynamic, substoichiometric, targeted to specific
subcellular compartments and prevalent on low-abundance regulatory proteins. The sugar is
also enzymatically and chemically labile, being subject to reversal by cellular glycosidases
and cleavage on a mass spectrometer. As with many protein kinases, the lack of a well-
defined consensus sequence for OGT has precluded the determination of in vivo
modification sites on the basis of the primary sequence. Here we highlight some chemical
approaches designed to overcome these challenges and advance a fundamental
understanding of O-GlcNAc.
Rapid, sensitive detection
Traditional methods for detecting O-GlcNAc glycosylation include the use of wheat germ
agglutinin (WGA) lectin81, pan-specific O-GlcNAc antibodies73,77 or radiolabeling using
β-1,4-galactosyltransferase (GalT)82, which transfers [3H]Gal from UDP-[3H]galactose to
terminal GlcNAc groups. Although these approaches have greatly facilitated studies of the
modification, many O-GlcNAc proteins still elude detection. For instance, tritium labeling
suffers from low sensitivity, often necessitating exposure times of several days to months.
O-GlcNAc antibodies and lectins have limited binding affinity and specificity, and therefore
are best suited for highly glycosylated proteins with several modification sites.
Recently, chemical approaches have been developed to tag O-GlcNAc proteins with reporter
groups such as biotin to enable more rapid, sensitive detection. Khidekel and co-workers
designed an unnatural substrate for GalT containing a ketone moiety at the C2 position of
UDP-galactose83 (Fig. 3a). An engineered enzyme with a single Y289L mutation that
enlarges the binding pocket84 was used to transfer the ketogalactose sugar onto O-GlcNAc
proteins of interest. Once transferred, the ketone functionality was reacted with an aminooxy
biotin derivative and detected by chemiluminescence using streptavidin conjugated to
horseradish peroxidase. This approach provides a significant improvement in sensitivity,
enabling detection of proteins beyond the reach of traditional methods (Fig. 3b). The biotin
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handle also facilitates isolation of the glycoproteins from cell or tissue extracts, thus
circumventing the need to develop purification procedures for each protein of interest. As
such, virtually any protein can be readily interrogated for the modification, and comparisons
can be made across specific functional classes. For instance, Tai and co-workers have
applied the approach to demonstrate that numerous transcriptional regulatory proteins are O-
GlcNAc glycosylated in vivo, including transcription factors, transcriptional coactivators and
corepressors85. A variant of this method is now commercially available, in which a UDP
azidogalactose substrate is used in conjunction with ‘click’ chemistry to transfer alkyne-
containing reporter groups86 (Fig. 3c).
A complementary strategy involves tagging O-GlcNAc–modified proteins through
metabolic labeling of living cells with N-azido-acetylglucosamine (GlcNAz)87. Vocadlo and
co-workers showed that the azido sugar is processed by enzymes in the hexosamine salvage
pathway and forms O-GlcNAz– modified proteins. The bioorthogonal azide moiety can then
be derivatized with a FLAG peptide or a biotin tag using the Staudinger ligation. Treatment
of Jurkat cells with peracetylated N-azidoacetylglucosamine led to labeling of the highly
glycosylated nuclear pore protein p62, as detected by immuno-precipitation of p62 and
western blotting. Although the labeling efficiency and sensitivity of this approach could not
be evaluated and may depend on cell type, the ability to incorporate bioorthogonal groups
selectively into O-GlcNAc proteins represents a powerful strategy for the detection of O-
GlcNAc proteins in living cells.
Mapping O-GlcNAc glycosylation sites
Mapping the sites of O-GlcNAc glycosylation within proteins is essential for elucidating the
functional roles of O-GlcNAc in specific biological contexts. Unfortunately, direct
observation of the O-GlcNAc moiety by mass spectrometry during collision-induced
dissociation (CID) is difficult, as the glycosidic linkage is labile and readily cleaved,
providing little peptide fragmentation44. Moreover, although OGT seems to favor sequences
rich in proline, serine and threonine residues44, there is no apparent consensus sequence that
directs the action of OGT.
The development of chemical tools coupled to mass spectrometry has greatly facilitated the
localization of O-GlcNAc to short peptide sequences within proteins, and this combination
can be used to determine exact glycosylation sites. One approach, which relies on β-
elimination followed by Michael addition with dithiothreitol (BEMAD), results in
replacement of the labile GlcNAc moiety with a more stable sulfide adduct50 (Fig. 4). As
this adduct is not cleaved upon CID, sites of glycosylation can be more readily determined.
However, selectivity controls must be carried out to distinguish O-GlcNAc from O-
phosphate and other O-linked carbohydrates. Extension of BEMAD to proteomic studies for
the high-throughput mapping of O-GlcNAc sites is an important future goal.
A second approach capitalizes on the ability to selectively biotinylate O-GlcNAc proteins
using ketone- or azide-containing UDP-galactose sugars as described above (Fig. 3). In
addition to isolating intact proteins, the biotin handle can be used to enrich O-GlcNAc
peptides following proteolytic digestion44. This enrichment step is essential for mass
spectrometric detection because the O-GlcNAc–modified species represents only a small
fraction of the total peptides. Unlike BEMAD, the approach enables direct detection of the
O-GlcNAc moiety by mass spectrometry, with the GlcNAc-ketogalactose-biotin tag
providing a unique fragmentation pattern for unambiguous identification of O-GlcNAc
peptides44. Notably, the strategy has been applied to both individual proteins and complex
mixtures to localize the modification to short sequences in more than 50 different proteins.
However, mapping exact glycosylation sites remains challenging in most cases owing to the
lability of the O-glycosidic linkage. As a potential solution to this problem, Khidekel and
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co-workers demonstrated that this ketogalactose-biotin tagging approach could be combined
with BEMAD to identify specific glycosylation sites on the HIV-1 Rev binding protein44.
Similarly, Wang and co-workers recently used azidogalactose-biotin tagging in conjunction
with BEMAD to map glycosylation sites on vimentin88.
Newer mass spectrometry approaches such as electron transfer dissociation (ETD) and
electron capture dissociation (ECD) promise to greatly accelerate our ability to identify O-
GlcNAc modification sites. ETD and ECD produce sequence-specific fragmentation of
peptides without the loss of labile post-translational modifications such as phosphorylation
and glycosylation89. As such, these approaches are ideal for mapping O-GlcNAc
glycosylation sites. Vosseller and co-workers demonstrated that ECD can be used to identify
modification sites on several neuronal proteins following enrichment of the glycopeptides by
lectin weak-affinity chromatography49. More recently, Khidekel and co-workers applied the
ketogalactose-biotin tagging approach in conjunction with ETD to map glycosylation sites
on proteins from rat brain lysates19. In contrast to ECD, which requires the use of Fourier
transform instrumentation, ETD can be carried out directly in appropriately modified ion
trap mass spectrometers. Thus, the speed, sensitivity and accessibility of ETD to most
laboratories make it an ideal emerging technology. With further methodological refinements
and advances in database search algorithms for fragment ions, we anticipate that ETD and
ECD will become increasingly powerful tools for the study of O-GlcNAc glycosylation.
Proteome-wide analyses
As described earlier, the analysis of O-GlcNAc on a proteome level has begun to reveal
exciting functional roles for O-GlcNAc in the brain. Chemical strategies to tag, enrich and
detect O-GlcNAc peptides and proteins have been instrumental in this regard, enabling the
first proteome-wide studies of O-GlcNAc. Specifically, the ketogalactose-biotin tagging
approach (Fig. 3) has been applied in combination with high-throughput LC-MS/MS
analysis to identify more than 45 O-GlcNAc–glycosylated proteins from the mammalian
brain19,44. Direct detection of the modified species was observed in each case, which
allowed mapping of the glycosylation sites to short peptide sequences. Notably, many of the
proteins identified participate in the regulation of gene expression (for example, CCR4–
NOT, SOX2, SRC1, HCF and TLE4), neuronal signaling (WNK1, bassoon, PDZ-GEF) and
synaptic plasticity (synGAP, synaptopodin), suggesting that O-GlcNAc may contribute to
neuronal communication processes. In another approach, Nandi and co-workers
metabolically labeled HeLa cells with N-(2-azido-acetyl) glucosamine90. Tryptic digestion
of the captured proteins led to the identification of 199 putative O-GlcNAc–modified
proteins. As the presence of the GlcNAc moiety was inferred rather than detected directly,
independent confirmation of the modification by immunoprecipitation was required and
demonstrated for 23 of the proteins.
Recently, biochemical tools such as antibodies and lectins have been exploited for proteomic
analyses of O-GlcNAc. Vosseller and co-workers used a uniquely packed, 39-foot lectin
affinity column to enrich O-GlcNAc peptides and identified 18 proteins from the
postsynaptic density fraction of murine brain tissue49. Antibody affinity chromatography
using a general O-GlcNAc antibody identified 45 putative O-GlcNAc proteins from COS7
cells88. The challenge with both approaches is that the weak binding affinity of antibodies
and lectins necessitates gentle washing conditions and can lead to false positives, such as
interacting proteins or nonspecific binding proteins. In many cases, further confirmation of
the presence of the modification can be provided by evaluating individually
immunoprecipitated proteins or by directly detecting O-GlcNAc–modified peptides by mass
spectrometry analysis.
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Together, proteome-wide studies have revealed that O-GlcNAc is a ubiquitous and abundant
modification found on proteins with considerable functional significance and breadth. In less
than 5 years, the number of known O-GlcNAc proteins has expanded from tens to hundreds,
with many more proteins yet to be discovered.
Small-molecule inhibitors of OGT and OGA
Historically, genetic manipulation of OGT and OGA activity in vivo has proven difficult.
Whole-animal and conditional deletions of the OGT gene have revealed that OGT is
essential for cell survival and mouse embryogenesis17,91. Modulation of OGT using small
interfering RNAs is complicated by the long half-life of the protein and often produces only
partial knockdown of OGT92. Although deletion of OGA in Caenorhabditis elegans leads to
metabolic changes and increased dauer formation93, no mammalian knockout of OGA has
yet been reported. These features have challenged efforts to study O-GlcNAc glycosylation
and have limited the use of conventional genetic tools to elucidate its role in cellular
processes.
A complementary approach involves the generation of pharmacological agents to inhibit
OGT and OGA. A well-established inhibitor of OGT, alloxan, shows multiple nonspecific
effects, such as inhibition of OGA94, glucokinase inhibition95 and formation of superoxide
radicals96. By screening a 64,416-member library of compounds using a novel fluorescence-
based assay, Gross and co-workers identified several promising new compounds that inhibit
OGT activity in vitro97 (Fig. 5a, compounds 1–3). These compounds were selective in
inhibiting OGT but not another related enzyme, MurG, which also uses UDP-GlcNAc as a
substrate. Recently, a benzoxazolinone compound (Fig. 5a, compound 1) was shown to
inhibit OGT activity in oocytes, where it prevents meiotic progression98. In the future, these
numerous, chemically distinct OGT inhibitors might be used in parallel to distinguish the
potential nonspecific effects of individual inhibitors in vivo.
Many of the early OGA inhibitors such as PUGNAc (O-(2-acetamido- 2-deoxy-D-
glucopyranosylidene)amino-N-phenylcarbamate) exhibit nonspecific activity toward β-
hexosaminidase99 and only partially inhibit the short isoform of OGA100. Recently, several
laboratories have designed more selective OGA inhibitors that either are structural variants
of early hexosaminidase inhibitors and/or have been rationally designed using information
about the enzyme active site. For instance, Macauley et al. and Knapp et al. functionalized
the nonspecific hexosaminidase inhibitor GlcNAc-thiazoline with longer alkyl chains or
fluoro or azido groups to generate new OGA inhibitors that show greater than 3,000-fold
selective inhibition of OGA over β-hexosaminidase101,102 (Fig. 5b, compounds 4–6). In
other studies, extending the N-acyl group of PUGNAc led to the creation of new inhibitors
with greater than ten-fold selectivity for OGA over β-hexosaminidase99,103. A drawback of
these compounds is that they inhibit OGA more weakly than PUGNAc. In response to this
problem, Dorfmeuller and co-workers designed a nagstatin derivative based on the crystal
structure of NagJ, a bacterial homolog of human OGA104 (Fig. 5b, compound 7). The
isobutanamido group at the N8 position (tetrahydroimidazopyridine numbering) provides
improved selectivity by fitting into a pocket that is larger than the corresponding pockets in
other hexosaminidases, whereas the phenethyl group at the C2 position offers stronger
inhibition (Ki = 4.6 ± 0.1 pM) for the bacterial homolog of OGA by interacting with a
solvent-exposed tryptophan residue. Nonetheless, a related nagstatin derivative still showed
weaker inhibition toward human OGA than PUGNAc105. More recently, Kim and co-
workers designed a compound that strongly inhibits the short isoform of OGA100 (Fig. 5,
compound 8), an isoform that is only partially inhibited by 1 mM PUGNAc. However,
selectivity may be an issue with this compound, as thiosulfonate moieties have been shown
to react with exposed cysteine residues of proteins106. Notably, compounds 4 and 7 have
been tested in cell culture and were shown to increase overall cellular O-GlcNAc levels.
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The discovery of potent, selective inhibitors of OGT and OGA provides powerful tools for
perturbing O-GlcNAc glycosylation in cells and in vivo. Application of these inhibitors in
specific contexts should reveal new insights into the functional roles of O-GlcNAc and
cellular mechanisms for the regulation of OGT and OGA.
Monitoring O-GlcNAc dynamics
The dynamic nature of O-GlcNAc is a unique characteristic that distinguishes it from other
forms of glycosylation. As described earlier, this feature has important implications for the
regulation of protein structure and function and the interplay with other post-translational
modifications. An exciting challenge in the future will be to understand the cellular
dynamics of the modification, as well as the signaling pathways and mechanisms by which
O-GlcNAc is regulated on specific proteins. Toward this end, several groups have developed
chemical approaches to monitor changes in O-GlcNAc glycosylation levels in response to
cellular stimuli.
Carrillo and co-workers designed a fluorescence resonance energy transfer (FRET)-based
sensor for the detection of O-GlcNAc dynamics in living cells107. Their sensor consisted of
two fluorophores (enhanced cyan and yellow fluorescent protein) separated by a known
peptide substrate for OGT and an O-GlcNAc lectin (GafD). Upon O-GlcNAc glycosylation,
the lectin was expected to bind the glycosylated peptide substrate and bring the two
fluorophores in close proximity, producing a stronger FRET signal (Fig. 6a). As anticipated,
an increase in FRET (7–30%) was observed upon stimulation of transfected HeLa cells with
PUGNAc and glucosamine. In the future, it will be interesting to examine changes in OGT
activity in response to a variety of cellular stimuli.
In addition to monitoring OGT activity, identifying the intracellular signaling pathways and
dynamics of O-GlcNAc glycosylation on specific protein substrates represents an important,
challenging goal. General O-GlcNAc antibodies (CTD110.6 and RL-2) have been extremely
valuable for measuring global changes in glycosylation in response to cellular stimuli73, 77.
However, a limitation of these antibodies is that they detect only a small subset of the O-
GlcNAc–modified proteins19, 83. Moreover, it remains difficult to identify the specific
proteins that undergo changes in glycosylation. In response to these challenges, Khidekel
and co-workers have developed a method to probe the dynamics of O-GlcNAc glycosylation
in vivo using quantitative proteomics19 (Fig. 6b). The quantitative isotopic and
chemoenzymatic tagging (QUIC-Tag) approach involves chemoenzymatically labeling
proteins from two different cell states (for example, stimulated versus unstimulated) with a
ketogalactose- biotin reporter group as described above. Following proteolytic digestion, the
peptides are isotopically labeled using reductive amination chemistry to distinguish the two
populations and subsequently combined. The biotinylated O-GlcNAc peptides are enriched
using avidin chromatography, then quantified and sequenced by mass spectrometry. Using
this approach, proteins undergoing dynamic changes in glycosylation can be identified, and
glycosylation changes at specific sites within proteins can be monitored in response to
cellular stimulation. Khidekel and co-workers found that O-GlcNAc glycosylation is
induced on certain proteins upon excitatory stimulation of the rodent brain in vivo. Whereas
some sites of glycosylation underwent robust changes in occupancy, other sites remained
unchanged, suggesting that O-GlcNAc is subject to complex regulation within neurons. The
reversible and highly regulated nature of O-GlcNAc, along with the observation that
excitatory stimulation induces glycosylation, supports the idea that OGlcNAc is an
important, regulatory modification in the brain.
More recently, Wang and co-workers used immunoaffinity chromatography in conjunction
with SILAC (stable isotope labeling with amino acids in cell culture), a well-established
method for quantitative proteomics108, to study the dynamic interplay between O-GlcNAc
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and phosphorylation by glycogen synthase kinase-3 (GSK3)88. Heavy and light isotope-
labeled cells were treated with lithium chloride to inhibit GSK3, and O-GlcNAc proteins of
interest were isolated by affinity chromatography using a general O-GlcNAc antibody.
Forty-five putative OGlcNAc– glycosylated proteins were identified by mass spectrometry,
ten of which showed enrichment after lithium chloride treatment, suggesting that these
proteins underwent increases in O-GlcNAc glycosylation. In four of the cases, the
glycosylation increases that were observed indirectly by mass spectrometry were confirmed
by immunoprecipitation. Interestingly, other proteins showed either no change or decreased
glycosylation, suggesting that a complex interplay is likely to exist between phosphorylation
and O-GlcNAc glycosylation within signaling networks.
With these new tools, in-depth studies of the dynamics of O-GlcNAc within cells are now
within reach. Understanding the molecular mechanisms by which this dynamic signaling
comes about and regulates specific proteins is a future challenge that promises to propel the
field in exciting new directions.
Conclusion and future challenges
Over the past decade, a surge of discoveries in O-GlcNAc glycosylation has revealed new
roles for this modification in the nervous system. O-GlcNAc is abundant in the brain and
present on many diverse proteins involved in transcription, neuronal signaling and synaptic
plasticity. Indeed, recent studies have begun to uncover the functional roles of O-GlcNAc,
its complex dynamics in the brain and the interplay between O-GlcNAc and
phosphorylation. Many of these discoveries have been accelerated by the development of
new chemical tools, such as those for detecting the O-GlcNAc modification in cells and for
inhibiting OGT and OGA. Combined with advances in mass spectrometry, these new
technologies have provided an unprecedented opportunity to define the O-GlcNAc
proteome, manipulate O-GlcNAc enzymes and explore the dynamics of this modification in
vivo.
Although the pace and scope of understanding O-GlcNAc has expanded considerably, much
remains to be discovered. Owing to the challenge of studying the modification, evidence
linking O-GlcNAc to specific biological functions has often been indirect or correlative.
This is particularly true in the brain, where the complexity of the nervous system and its
unique technical challenges (for example, postmitotic cells, the complex organization of the
brain, the presence of multiple cell types and the blood-brain barrier) render O-GlcNAc
more difficult to investigate. Nonetheless, in-depth functional studies on proteins will be
essential in the future to determine the roles of O-GlcNAc in neuronal-specific contexts.
The development of new chemical tools to produce homogeneously glycosylated proteins
will represent an important step toward this goal. Unlike phosphorylation, O-GlcNAc
glycosylation cannot be readily mimicked by any naturally occurring amino acid. At best,
alanine mutagenesis of specific glycosylation sites within proteins can be used to effect
changes in function. Chemical methods such as nonsense suppression109 and native
chemical ligation110 may allow for the construction of O-GlcNAc–glycosylated proteins in
vitro and in cells. In the future, these methods may provide new insights into whether and
how O-GlcNAc glycosylation affects protein structure, modulates protein-protein
interactions and influences other post-translational modifications.
One of the central challenges of neuroscience is to understand the unique molecular and
cellular heterogeneity of the brain as it relates to systems-level phenomena such as learning
and memory. Sensitive methods to detect the modification on small subpopulations of cells
or proteins will be required to dissect the role of O-GlcNAc in fear, addiction and other
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complex learning and memory models. Despite significant progress, faster, higher-
throughput methods are still needed to identify O-GlcNAc proteins and study O-GlcNAc
dynamics in vivo. For instance, the ability to directly monitor the glycosylation status of
specific proteins using chemical tagging approaches or site-specific O-GlcNAc antibodies
will be essential. To facilitate the production of O-GlcNAc antibodies, facile synthetic
routes to access O-GlcNAc– modified peptides are needed. Moreover, the continued
development of methods to precisely map glycosylation sites, particularly on small
quantities of material and on selected proteins of interest, will be crucial for any functional
studies.
New sensitive and selective OGT and OGA inhibitors will be important tools for finely
dissecting the role of each enzyme in neuronal function and dysfunction. Given the diversity
of OGT and OGA substrates, and the lethality of deleting the OGT gene in mice, creative
new genetic or chemical approaches are needed to more selectively target functional subsets
of OGT and OGA by interfering, for instance, with the enzymes in certain subcellular
compartments.
From the time of its discovery, the appeal of O-GlcNAc has been both the intrigue of
understanding its unique biology and the great technical challenges associated with its study.
Over the past 5 years, we have seen a surge of new chemistry designed to meet these
obstacles. Strengthened by an arsenal of chemical tools, the future of O-GlcNAc is primed
for new and exciting discoveries.
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Figure 1.
O-GlcNAc glycosylation is the addition of β-N-acetylglucosamine to serine or threonine
residues of proteins. OGT, O-GlcNAc transferase; OGA, β-N-acetylglucosaminidase.
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Figure 2.
O-GlcNAc proteome from rodent brain tissue. Approximately 31% of the known O-GlcNAc
proteins are involved in neuronal communication and signaling, 24% participate in
transcriptional regulation, and 21% are associated with cytoskeletal structures. Proteins were
classified according to categories described by Schoof et al.111
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Figure 3.
Strategy for chemically tagging O-GlcNAc proteins. (a) An engineered mutant GalT
enzyme transfers the UDP-ketogalactose substrate onto O-GlcNAc proteins. The ketone
functionality is then reacted with an aminooxy biotin derivative. Tagged O-GlcNAc
glycoproteins are then detected by chemiluminescence or isolated by streptavidin affinity
chromatography. Adapted from ref. 19. (b) Detection of αA-crystallin using the
ketogalactose-biotin tagging approach and comparison with other methods. The chemical
tagging approach provides significantly improved sensitivity relative to antibodies and
lectins. 0.75 μg of αA-crystallin was used for the ketogalactose labeling method; 5 μg of
protein was used for the lectins and antibodies. (c) The UDP-ketogalactose substrate can be
replaced with the UDP-azidogalactose substrate shown, and an azide-alkyne [3+2]
cycloaddition reaction can be used to attach biotin or fluorescent dyes.
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Figure 4.
The BEMAD strategy for mapping glycosylation sites. In this approach, the GlcNAc sugar
undergoes a β-elimination reaction. Michael addition with dithiothreitol produces a sulfide
adduct that is stable to MS/MS analysis.
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Figure 5.
Small-molecule inhibitors of O-GlcNAc transferase (OGT) and β-N-acetylglucosaminidase
(OGA). (a) OGT inhibitors (1–3) identified by screening a 64,416-member library of
compounds. The benzoxazolinone compound 1 inhibits OGT activity in oocytes and
prevents meiotic progression. (b) Representative OGA inhibitors (4–8) with enhanced
selectivity for OGA over β-hexosaminidase.
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Figure 6.
Chemical tools for monitoring O-GlcNAc dynamics. (a) A fluorescence resonance energy
transfer (FRET)-based sensor designed to detect the dynamics of O-GlcNAc glycosylation
in living cells. Upon glycosylation, binding of the GafD lectin to the O-GlcNAc moiety
induces a conformational change and produces a stronger FRET signal. CFP, enhanced cyan
fluorescent protein; YFP, yellow fluorescent protein. (b) The quantitative isotopic and
chemoenzymatic tagging (QUIC-Tag) approach for quantitative proteomics. Proteins from
two different cell states are tagged with a ketogalactose-biotin group as shown in Figure 3a.
After proteolytic digestion, the peptides are isotopically labeled and combined. The
biotinylated O-GlcNAc peptides are captured using avidin chromatography, and quantified
and sequenced by mass spectrometry. This approach enables the identification of O-GlcNAc
proteins undergoing changes in glycosylation in response to cellular stimuli and allows for
those changes to be monitored at specific specific sites within proteins. Adapted from ref.
19.
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